ScPharmaceuticals Long Term Debt 2016-2024 | SCPH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ScPharmaceuticals long term debt from 2016 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ScPharmaceuticals long term debt from 2016 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$160.1B
Vertex Pharmaceuticals (VRTX)	$123.9B
Gilead Sciences (GILD)	$122.2B
Bristol Myers Squibb (BMY)	$116.5B
CSL (CSLLY)	$82.8B
Regeneron Pharmaceuticals (REGN)	$79.3B
GSK (GSK)	$75.4B
Argenex SE (ARGX)	$40B
Alnylam Pharmaceuticals (ALNY)	$35.9B
BioNTech SE (BNTX)	$28.8B
BeiGene (ONC)	$22.4B
Biogen (BIIB)	$20.7B
Illumina (ILMN)	$19.5B
Insmed (INSM)	$14.5B
Incyte (INCY)	$14.4B
Intra-Cellular Therapies (ITCI)	$13.5B
Moderna (MRNA)	$12.9B
Genmab (GMAB)	$12.8B
Genmab (GNMSF)	$12.7B
BioMarin Pharmaceutical (BMRN)	$12.3B
Bio-Techne Corp (TECH)	$11.9B
Vaxcyte (PCVX)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Sarepta Therapeutics (SRPT)	$10.7B
Exact Sciences (EXAS)	$10B
Bio-Rad Laboratories (BIO.B)	$9.6B
Exelixis (EXEL)	$9.6B
QIAGEN (QGEN)	$9.4B
Repligen (RGEN)	$9.1B
Roivant Sciences (ROIV)	$7.9B